Lifearc

Lifearc company information, Employees & Contact Information

Explore related pages

Related company profiles:

LifeArc® is a medical research charity making life science life changing, transforming promising life science ideas into medical breakthroughs that change patients’ lives. We are self-funding and specialise in early-stage translation – advancing lab-based scientific discoveries to a point at which they can be developed into the next generation of diagnostics, treatments and cures. We have been doing this for more than 25 years and our work has resulted in a diagnostic for antibiotic resistance and four licensed medicines. This includes Keytruda®(cancer), Actemra® (rheumatoid arthritis), Tysabri® (multiple sclerosis) and Entyvio® (Crohn’s disease) and a test for antimicrobial resistance. Find out more about our work at www.lifearc.org or follow us on LinkedIn or Twitter (@lifearc1)

Company Details

Employees
419
Address
7-12 Tavistock Square, London,wc1h 9lt,united Kingdom
Phone
4402073912700
Email
in****@****arc.org
Industry
Non-Profit Organizations
Keywords
London.
HQ
London
Looking for a particular Lifearc employee's phone or email?

Lifearc Questions

News

Design and Synthesis of Pyrazoline Inhibitors of SARS-CoV-2 NSP14 - ACS Publications

Design and Synthesis of Pyrazoline Inhibitors of SARS-CoV-2 NSP14 ACS Publications

SpringWorks Therapeutics Launches with $103M in Series A Funding and Rights to Four Clinical Programs - Bain Capital

SpringWorks Therapeutics Launches with $103M in Series A Funding and Rights to Four Clinical Programs Bain Capital

FDA approves trial to advance pioneering treatment for Hereditary Spastic Paraplegia (HSP) | News - The University of Sheffield

FDA approves trial to advance pioneering treatment for Hereditary Spastic Paraplegia (HSP) | News The University of Sheffield

LifeArc Ventures - six new investments, portfolio progress and an expanding investment team - PR Newswire

LifeArc Ventures - six new investments, portfolio progress and an expanding investment team PR Newswire

LifeArc Translational Summit on MND and Rare Dementias - UK DRI

LifeArc Translational Summit on MND and Rare Dementias UK DRI

Illumina Invests in £30M Venture Fund to Advance Breakthroughs in Human Health - Illumina

Illumina Invests in £30M Venture Fund to Advance Breakthroughs in Human Health Illumina

Dr. Sam Barrell CBE appointed as CEO of LifeArc - Yahoo Finance

Dr. Sam Barrell CBE appointed as CEO of LifeArc Yahoo Finance

Targeted protein degradation in CNS disorders: a promising route to novel therapeutics? - Frontiers

Targeted protein degradation in CNS disorders: a promising route to novel therapeutics? Frontiers

LifeArc Childhood Cancer Translation Challenge launched - Brain Tumour Research

LifeArc Childhood Cancer Translation Challenge launched Brain Tumour Research

AbbVie acquires LifeArc portfolio company DJS Antibodies - Labiotech.eu

AbbVie acquires LifeArc portfolio company DJS Antibodies Labiotech.eu

Dr. Thomas Marek Wallach is the first German scientist to be awarded with the LifeArc-AUTM Fellowship - Berlin Institute of Health

Dr. Thomas Marek Wallach is the first German scientist to be awarded with the LifeArc-AUTM Fellowship Berlin Institute of Health

LifeArc to land in London’s King’s Cross - Estates Gazette

LifeArc to land in London’s King’s Cross Estates Gazette

New £10.4M research centre will unlock new tests, treatments and cures for people living with rare kidney diseases - Kidney Research UK

New £10.4M research centre will unlock new tests, treatments and cures for people living with rare kidney diseases Kidney Research UK

LifeArc makes $30M Kymab investment to access antibody tech - Fierce Biotech

LifeArc makes $30M Kymab investment to access antibody tech Fierce Biotech

Charity LifeArc sells rights to Keytruda for more than $1bn - Pharmaceutical Technology

Charity LifeArc sells rights to Keytruda for more than $1bn Pharmaceutical Technology

Maxion Therapeutics Raises $72 million (£58 million) in an - GlobeNewswire

Maxion Therapeutics Raises $72 million (£58 million) in an GlobeNewswire

LifeArc, née MRC Technology, sets up high-risk seed fund - Fierce Biotech

LifeArc, née MRC Technology, sets up high-risk seed fund Fierce Biotech

Drug repurposing for rare: progress and opportunities for the rare disease community - Frontiers

Drug repurposing for rare: progress and opportunities for the rare disease community Frontiers

LifeArc steers new-found financial clout into expanded drugs research - Financial Times

LifeArc steers new-found financial clout into expanded drugs research Financial Times

Cancer Research UK, LifeArc and Ono Pharma form cancer immunotherapy alliance - Cancer Research UK - Cancer News

Cancer Research UK, LifeArc and Ono Pharma form cancer immunotherapy alliance Cancer Research UK - Cancer News

VC firm LifeArc sells first portfolio company as dermatitis-focused Ducentis bought by Arcutis for $30M - Fierce Biotech

VC firm LifeArc sells first portfolio company as dermatitis-focused Ducentis bought by Arcutis for $30M Fierce Biotech

News - MRCT now LifeArc - EVOluTION - Queen Mary University of London

News - MRCT now LifeArc - EVOluTION Queen Mary University of London

UK's LifeArc charity nets $1.3 billion Keytruda windfall - pharmaphorum

UK's LifeArc charity nets $1.3 billion Keytruda windfall pharmaphorum

LifeArc receives $1.2b in Keytruda royalties - PharmaTimes

LifeArc receives $1.2b in Keytruda royalties PharmaTimes

LifeArc and Milner Therapeutics Institute Announce a New Partnership in AI for Target Discovery - Technology Networks

LifeArc and Milner Therapeutics Institute Announce a New Partnership in AI for Target Discovery Technology Networks

A vision of the future with C-Further - Cancer Research UK - Cancer News

A vision of the future with C-Further Cancer Research UK - Cancer News

Rare disease research at Cambridge receives major boost with launch of two new centres - University of Cambridge

Rare disease research at Cambridge receives major boost with launch of two new centres University of Cambridge

University of Sheffield spinout company to pioneer novel therapies for genetic neurological diseases - The University of Sheffield

University of Sheffield spinout company to pioneer novel therapies for genetic neurological diseases The University of Sheffield

LifeArc, Dstl and CDRD Collaborate to Identify Antibacterial Drug Targets - Technology Networks

LifeArc, Dstl and CDRD Collaborate to Identify Antibacterial Drug Targets Technology Networks

King's College London and LifeArc team up to accelerate MND treatment development - King's College London

King's College London and LifeArc team up to accelerate MND treatment development King's College London

LifeArc provides £5 million funding to increase understanding of the… - genomicsengland.co.uk

LifeArc provides £5 million funding to increase understanding of the… genomicsengland.co.uk

April: lifearc-kidney | News and features - University of Bristol

April: lifearc-kidney | News and features University of Bristol

LifeArc takes $30m equity stake in Kymab, gains access to antibody tech - PMLiVE

LifeArc takes $30m equity stake in Kymab, gains access to antibody tech PMLiVE

Translational efforts transformed with £30 million LifeArc partnership - UK DRI

Translational efforts transformed with £30 million LifeArc partnership UK DRI

WACCBIP Joins Forces with The Francis Crick Institute and LifeArc to Empower African Scientists - Modern Ghana

WACCBIP Joins Forces with The Francis Crick Institute and LifeArc to Empower African Scientists Modern Ghana

Funding (£10 Million) for Development and Testing of Therapeutics to Treat COVID-19 - fundsforNGOs

Funding (£10 Million) for Development and Testing of Therapeutics to Treat COVID-19 fundsforNGOs

LifeArc charity raises £1bn from sale of royalty interest in immunotherapy drug - Civil Society Media

LifeArc charity raises £1bn from sale of royalty interest in immunotherapy drug Civil Society Media

APO – - Journal du Mali

APO – Journal du Mali

Medical research organisation signs for 70,000 sq ft King’s Cross HQ - BE News

Medical research organisation signs for 70,000 sq ft King’s Cross HQ BE News

GVK Bio, LifeArc advance research in medicine - The Hans India

GVK Bio, LifeArc advance research in medicine The Hans India

WACCBIP partners Francis Crick Institute, LifeArc to empower African scientists - Ghana Business News

WACCBIP partners Francis Crick Institute, LifeArc to empower African scientists Ghana Business News

CC Bio and Reflection Therapeutics share LifeArc reward - Cambridge Independent

CC Bio and Reflection Therapeutics share LifeArc reward Cambridge Independent

Accelerate@Babraham gets LifeArc cash injection - Cambridge Independent

Accelerate@Babraham gets LifeArc cash injection Cambridge Independent

Top Lifearc Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant